Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study.
증례연속
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
15 cases of PE/T during BTKi therapy.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The meta-analysis showed a significantly increased risk of PE/T with BTKi therapy (OR 3.25; 95% CI 1.02-10.35; = 0.01; I=0%). These results suggest that PE/T may represent a rare but clinically meaningful cardiac toxicity of BTKi therapy.
Bruton tyrosine kinase inhibitors (BTKi) have a unique cardiovascular toxicity profile.
- 95% CI 1.02-10.35
- 연구 설계 systematic review
APA
Hofstetter L, Shimony S, et al. (2026). Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study.. Leukemia & lymphoma, 67(4), 860-867. https://doi.org/10.1080/10428194.2025.2612248
MLA
Hofstetter L, et al.. "Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study.." Leukemia & lymphoma, vol. 67, no. 4, 2026, pp. 860-867.
PMID
41587086 ↗
Abstract 한글 요약
Bruton tyrosine kinase inhibitors (BTKi) have a unique cardiovascular toxicity profile. We investigated pericardial effusion and tamponade (PE/T) as a potential cardiac complication associated with BTKi therapy. We employed a multi-modal approach: (1) a case series (2) a prevalence analysis using institutional and National Health Oragnization Maintanance (HMO) registry data; and (3) a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing BTKi- and non-BTKi-based regimens in CLL. We identified 15 cases of PE/T during BTKi therapy. In our institutional cohort ( = 750), PE/T prevalence was 2.6% among BTKi-treated patients vs. 0.17% in non-BTKi-treated patients (RR 15.48; = 0.0072). In the HMO registry ( = 5917), BTKi-associated PE/T prevalence was 0.78%, with an RR of 3.09 ( = 0.029). The meta-analysis showed a significantly increased risk of PE/T with BTKi therapy (OR 3.25; 95% CI 1.02-10.35; = 0.01; I=0%). These results suggest that PE/T may represent a rare but clinically meaningful cardiac toxicity of BTKi therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Cardiac Tamponade
- Pericardial Effusion
- Protein Kinase Inhibitors
- Agammaglobulinaemia Tyrosine Kinase
- Male
- Female
- Aged
- Middle Aged
- Leukemia
- Lymphocytic
- Chronic
- B-Cell
- Cardiotoxicity
- Prevalence
- 80 and over
- Registries
- Antineoplastic Combined Chemotherapy Protocols
- Bruton tyrosine kinase inhibitors (BTKI)
- Chronic lymphocytic lymphoma
- cardiovascular toxicity
- pericardial effusion
- tamponade
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.